<?xml version="1.0" encoding="UTF-8"?><!-- generator="podbean/5.5" -->
<rss version="2.0"
     xmlns:content="http://purl.org/rss/1.0/modules/content/"
     xmlns:atom="http://www.w3.org/2005/Atom"
     xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd"
     xmlns:spotify="http://www.spotify.com/ns/rss"
     xmlns:podcast="https://podcastindex.org/namespace/1.0"
    xmlns:media="http://search.yahoo.com/mrss/">

<channel>
    <title>A Prescription for Fair Drug Pricing</title>
    <atom:link href="https://feed.podbean.com/instituteforclinicalandeconomicreview/feed.xml" rel="self" type="application/rss+xml"/>
    <link>https://instituteforclinicalandeconomicreview.podbean.com</link>
    <description>By Jason L. Crowell, MD Jerome H. Grossman MD Graduate Fellow, Harvard Kennedy School Neurologist, Beth Israel Deaconess Medical Center;  Steve Pearson, Founder and President, ICER, Lecturer, Department of Population Medicine, Harvard Medical School</description>
    <pubDate>Mon, 21 Dec 2020 08:11:32 -0500</pubDate>
    <generator>https://podbean.com/?v=5.5</generator>
    <language>en</language>
        <copyright>Copyright 2020 All rights reserved.</copyright>
    <category>Health &amp; Fitness:Medicine</category>
    <ttl>1440</ttl>
          <itunes:summary>By Jason L. Crowell, MD Jerome H. Grossman MD Graduate Fellow, Harvard Kennedy School Neurologist, Beth Israel Deaconess Medical Center;  Steve Pearson, Founder and President, ICER, Lecturer, Department of Population Medicine, Harvard Medical School</itunes:summary>
        <itunes:author>instituteforclinicalandeconomicreview</itunes:author>
	<itunes:category text="Health &amp; Fitness">
		<itunes:category text="Medicine" />
	</itunes:category>
    <itunes:owner>
        <itunes:name>instituteforclinicalandeconomicreview</itunes:name>
            </itunes:owner>
    	<itunes:block>No</itunes:block>
	<itunes:explicit>false</itunes:explicit>
    <itunes:image href="https://pbcdn1.podbean.com/imglogo/image-logo/9901581/ICER_Podcast_1400_version2.png" />
    <image>
        <url>https://pbcdn1.podbean.com/imglogo/image-logo/9901581/ICER_Podcast_1400_version2.png</url>
        <title>A Prescription for Fair Drug Pricing</title>
        <link>https://instituteforclinicalandeconomicreview.podbean.com</link>
        <width>144</width>
        <height>144</height>
    </image>
    <item>
        <title>How doctors can be a part of the solution</title>
        <itunes:title>How doctors can be a part of the solution</itunes:title>
        <link>https://instituteforclinicalandeconomicreview.podbean.com/e/how-doctors-can-be-a-part-of-the-solution/</link>
                    <comments>https://instituteforclinicalandeconomicreview.podbean.com/e/how-doctors-can-be-a-part-of-the-solution/#comments</comments>        <pubDate>Mon, 21 Dec 2020 08:11:32 -0500</pubDate>
        <guid isPermaLink="false">instituteforclinicalandeconomicreview.podbean.com/f6b2d7cc-ce3a-3ced-af2e-fc5ceeccc16a</guid>
                                    <description><![CDATA[<p>What can physicians do in their hospitals and communities to advocate for fair drug prices? What questions should we ask our patients to assess for financial toxicity? In the final episode of the season, we discuss the steps doctors can be taking now to help solve the drug pricing problem.</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>What can physicians do in their hospitals and communities to advocate for fair drug prices? What questions should we ask our patients to assess for financial toxicity? In the final episode of the season, we discuss the steps doctors can be taking now to help solve the drug pricing problem.</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/bxcn7s/ICER_Podcast_Episode_8_final6zo11.mp3" length="23529932" type="audio/mpeg"/>
        <itunes:summary><![CDATA[What can physicians do in their hospitals and communities to advocate for fair drug prices? What questions should we ask our patients to assess for financial toxicity? In the final episode of the season, we discuss the steps doctors can be taking now to help solve the drug pricing problem.]]></itunes:summary>
        <itunes:author>instituteforclinicalandeconomicreview</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>980</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>8</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>What else makes a drug “valuable”?</title>
        <itunes:title>What else makes a drug “valuable”?</itunes:title>
        <link>https://instituteforclinicalandeconomicreview.podbean.com/e/what-else-makes-a-drug-valuable/</link>
                    <comments>https://instituteforclinicalandeconomicreview.podbean.com/e/what-else-makes-a-drug-valuable/#comments</comments>        <pubDate>Mon, 14 Dec 2020 09:56:02 -0500</pubDate>
        <guid isPermaLink="false">instituteforclinicalandeconomicreview.podbean.com/7c747a68-9ebd-34de-a9a7-ebf13f5d4ac1</guid>
                                    <description><![CDATA[<p>If we only look at the benefits that a drug provides to those patients who take it, we may underestimate its value by ignoring the benefits it provides to the broader healthcare system. In episode 7, we reveal some of the other reasons that can make a drug more valuable than first meets the eye.</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>If we only look at the benefits that a drug provides to those patients who take it, we may underestimate its value by ignoring the benefits it provides to the broader healthcare system. In episode 7, we reveal some of the other reasons that can make a drug more valuable than first meets the eye.</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/qfgsrv/ICER_Podcast_Episode_7_final7nmjb.mp3" length="29156766" type="audio/mpeg"/>
        <itunes:summary><![CDATA[If we only look at the benefits that a drug provides to those patients who take it, we may underestimate its value by ignoring the benefits it provides to the broader healthcare system. In episode 7, we reveal some of the other reasons that can make a drug more valuable than first meets the eye.]]></itunes:summary>
        <itunes:author>instituteforclinicalandeconomicreview</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1214</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>7</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Cost-effectiveness 101</title>
        <itunes:title>Cost-effectiveness 101</itunes:title>
        <link>https://instituteforclinicalandeconomicreview.podbean.com/e/cost-effectiveness-101/</link>
                    <comments>https://instituteforclinicalandeconomicreview.podbean.com/e/cost-effectiveness-101/#comments</comments>        <pubDate>Mon, 07 Dec 2020 08:05:54 -0500</pubDate>
        <guid isPermaLink="false">instituteforclinicalandeconomicreview.podbean.com/18a2dba9-3d42-3172-b7ef-c2f76ab60e8a</guid>
                                    <description><![CDATA[<p>If a “fair” price rewards the benefit a drug provides, how do we quantify those benefits—both to the patient and, more broadly, to society? Cost-effectiveness analysis is the tool we can use to quantify a drug’s benefit in a way that can be compared across treatments.</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>If a “fair” price rewards the benefit a drug provides, how do we quantify those benefits—both to the patient and, more broadly, to society? Cost-effectiveness analysis is the tool we can use to quantify a drug’s benefit in a way that can be compared across treatments.</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/re6cnt/ICER_Podcast_Episode_6_finalbkkxn.mp3" length="37708762" type="audio/mpeg"/>
        <itunes:summary><![CDATA[If a “fair” price rewards the benefit a drug provides, how do we quantify those benefits—both to the patient and, more broadly, to society? Cost-effectiveness analysis is the tool we can use to quantify a drug’s benefit in a way that can be compared across treatments.]]></itunes:summary>
        <itunes:author>instituteforclinicalandeconomicreview</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1570</itunes:duration>
                <itunes:episode>6</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Who sets a drug’s price, and how do we know it’s fair?</title>
        <itunes:title>Who sets a drug’s price, and how do we know it’s fair?</itunes:title>
        <link>https://instituteforclinicalandeconomicreview.podbean.com/e/who-sets-a-drug-s-price-and-how-do-we-know-it-s-fair/</link>
                    <comments>https://instituteforclinicalandeconomicreview.podbean.com/e/who-sets-a-drug-s-price-and-how-do-we-know-it-s-fair/#comments</comments>        <pubDate>Mon, 30 Nov 2020 09:38:24 -0500</pubDate>
        <guid isPermaLink="false">instituteforclinicalandeconomicreview.podbean.com/83f84541-6e70-3c98-b62d-3df07da15d31</guid>
                                    <description><![CDATA[<p>In episode 5, we review the variety of approaches one might take to settle on what the “fair” price of a drug should be. The most logical solution to this problem is to price the value—set a drug’s price commensurate with the clinical benefits it provides.  </p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In episode 5, we review the variety of approaches one might take to settle on what the “fair” price of a drug should be. The most logical solution to this problem is to <em>price the value</em>—set a drug’s price commensurate with the clinical benefits it provides.  </p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/ziu2v3/ICER_Podcast_Episode_5_final62c04.mp3" length="32240824" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In episode 5, we review the variety of approaches one might take to settle on what the “fair” price of a drug should be. The most logical solution to this problem is to price the value—set a drug’s price commensurate with the clinical benefits it provides.  ]]></itunes:summary>
        <itunes:author>instituteforclinicalandeconomicreview</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1342</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>5</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>What’s in it for me? Incentives for making new drugs</title>
        <itunes:title>What’s in it for me? Incentives for making new drugs</itunes:title>
        <link>https://instituteforclinicalandeconomicreview.podbean.com/e/what-s-in-it-for-me-incentives-for-making-new-drugs/</link>
                    <comments>https://instituteforclinicalandeconomicreview.podbean.com/e/what-s-in-it-for-me-incentives-for-making-new-drugs/#comments</comments>        <pubDate>Mon, 23 Nov 2020 08:56:40 -0500</pubDate>
        <guid isPermaLink="false">instituteforclinicalandeconomicreview.podbean.com/32007fbd-7532-3497-aa73-38d2a6bfd368</guid>
                                    <description><![CDATA[<p>What motivates a drug manufacturer to create a drug in the first place? How do firms stretch the limits of these incentives? In episode 4, we discuss how  the “ecosystem” of drug development in the US has led to truly remarkable innovation but also runaway drug prices.</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>What motivates a drug manufacturer to create a drug in the first place? How do firms stretch the limits of these incentives? In episode 4, we discuss how  the “ecosystem” of drug development in the US has led to truly remarkable innovation but also runaway drug prices.</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/ifszu3/ICER_Podcast_Episode_4_final7lkt8.mp3" length="39481149" type="audio/mpeg"/>
        <itunes:summary><![CDATA[What motivates a drug manufacturer to create a drug in the first place? How do firms stretch the limits of these incentives? In episode 4, we discuss how  the “ecosystem” of drug development in the US has led to truly remarkable innovation but also runaway drug prices.]]></itunes:summary>
        <itunes:author>instituteforclinicalandeconomicreview</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1644</itunes:duration>
                <itunes:episode>4</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>From Pharma to the Medicine Cabinet: Who Manages the Drugs?</title>
        <itunes:title>From Pharma to the Medicine Cabinet: Who Manages the Drugs?</itunes:title>
        <link>https://instituteforclinicalandeconomicreview.podbean.com/e/from-pharma-to-the-medicine-cabinet-who-manages-the-drugs/</link>
                    <comments>https://instituteforclinicalandeconomicreview.podbean.com/e/from-pharma-to-the-medicine-cabinet-who-manages-the-drugs/#comments</comments>        <pubDate>Mon, 16 Nov 2020 09:24:57 -0500</pubDate>
        <guid isPermaLink="false">instituteforclinicalandeconomicreview.podbean.com/b9772c77-d671-3f83-8ddc-c85be6032194</guid>
                                    <description><![CDATA[<p>Drugmakers, pharmacies, wholesale distributors, physicians, pharmacy benefit managers—the world of prescription drugs can seem extraordinarily complex. In episode 3, we disentangle this spider’s web and answer the question: who decides how much our patients pay at the pharmacy?</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>Drugmakers, pharmacies, wholesale distributors, physicians, pharmacy benefit managers—the world of prescription drugs can seem extraordinarily complex. In episode 3, we disentangle this spider’s web and answer the question: who decides how much our patients pay at the pharmacy?</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/n9n273/ICER_Podcast_Episode_3_final770lz.mp3" length="36572375" type="audio/mpeg"/>
        <itunes:summary>Drugmakers, pharmacies, wholesale distributors, physicians, pharmacy benefit managers—the world of prescription drugs can seem extraordinarily complex. In episode 3, we disentangle this spider’s web and answer the question: who decides how much our patients pay at the pharmacy?</itunes:summary>
        <itunes:author>instituteforclinicalandeconomicreview</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1523</itunes:duration>
                <itunes:episode>3</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Tradeoffs</title>
        <itunes:title>Tradeoffs</itunes:title>
        <link>https://instituteforclinicalandeconomicreview.podbean.com/e/tradeoffs-1604937056/</link>
                    <comments>https://instituteforclinicalandeconomicreview.podbean.com/e/tradeoffs-1604937056/#comments</comments>        <pubDate>Mon, 09 Nov 2020 10:51:32 -0500</pubDate>
        <guid isPermaLink="false">instituteforclinicalandeconomicreview.podbean.com/4cd9f72d-1280-309b-9ec1-11df4e96c172</guid>
                                    <description><![CDATA[<p>Whenever we choose to spend on one thing instead of another, we pay an opportunity cost. And, just like in life, healthcare is an either/or decision. Patients face decisions about how to spend their money on healthcare, just like insurance companies and governments must decide how to spend their finite dollars on healthcare.</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>Whenever we choose to spend on one thing instead of another, we pay an opportunity cost. And, just like in life, healthcare is an either/or decision. Patients face decisions about how to spend their money on healthcare, just like insurance companies and governments must decide how to spend their finite dollars on healthcare.</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/jjb6uv/ICER_Podcast_Episode_2_final9fpfb.mp3" length="22244652" type="audio/mpeg"/>
        <itunes:summary>Whenever we choose to spend on one thing instead of another, we pay an opportunity cost. And, just like in life, healthcare is an either/or decision. Patients face decisions about how to spend their money on healthcare, just like insurance companies and governments must decide how to spend their finite dollars on healthcare.</itunes:summary>
        <itunes:author>instituteforclinicalandeconomicreview</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>926</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>2</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>Financial Toxicity</title>
        <itunes:title>Financial Toxicity</itunes:title>
        <link>https://instituteforclinicalandeconomicreview.podbean.com/e/financial-toxicity/</link>
                    <comments>https://instituteforclinicalandeconomicreview.podbean.com/e/financial-toxicity/#comments</comments>        <pubDate>Mon, 02 Nov 2020 10:34:06 -0500</pubDate>
        <guid isPermaLink="false">instituteforclinicalandeconomicreview.podbean.com/dc9653ea-2d7a-3551-80b4-9d550741bd35</guid>
                                    <description><![CDATA[<p>In the first episode of the series, we discuss the problem of skyrocketing drug prices and the harmful effects they have on our patients. Not only must patients decide what their medications are worth to them, but payers introduce barriers that limit patients’ access to care. More broadly, we also review the ways that drug prices affect all of our society, via rising insurance premiums and taxes.</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In the first episode of the series, we discuss the problem of skyrocketing drug prices and the harmful effects they have on our patients. Not only must patients decide what their medications are worth to them, but payers introduce barriers that limit patients’ access to care. More broadly, we also review the ways that drug prices affect all of our society, via rising insurance premiums and taxes.</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/m9yshj/ICER_Podcast_Episode_1_final9ns5n.mp3" length="24446364" type="audio/mpeg"/>
        <itunes:summary><![CDATA[In the first episode of the series, we discuss the problem of skyrocketing drug prices and the harmful effects they have on our patients. Not only must patients decide what their medications are worth to them, but payers introduce barriers that limit patients’ access to care. More broadly, we also review the ways that drug prices affect all of our society, via rising insurance premiums and taxes.]]></itunes:summary>
        <itunes:author>instituteforclinicalandeconomicreview</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>1018</itunes:duration>
        <itunes:season>1</itunes:season>
        <itunes:episode>1</itunes:episode>
        <itunes:episodeType>full</itunes:episodeType>
            </item>
    <item>
        <title>COMING SOON: A Prescription for Fair Drug Pricing</title>
        <itunes:title>COMING SOON: A Prescription for Fair Drug Pricing</itunes:title>
        <link>https://instituteforclinicalandeconomicreview.podbean.com/e/introduction-to-a-prescription-for-fair-drug-prices/</link>
                    <comments>https://instituteforclinicalandeconomicreview.podbean.com/e/introduction-to-a-prescription-for-fair-drug-prices/#comments</comments>        <pubDate>Thu, 15 Oct 2020 14:48:45 -0400</pubDate>
        <guid isPermaLink="false">instituteforclinicalandeconomicreview.podbean.com/b1534922-6cac-3df2-acdc-75b79f70fd28</guid>
                                    <description><![CDATA[<p>In a new podcast series from the Institute for Clinical and Economic Review (ICER), neurologist Dr. Jason Crowell sits down with ICER’s President Dr. Steve Pearson to pry open the black box of US drug pricing and to wrestle with each of the financial and ethical tensions that undergird our current medical infrastructure. A must-listen for physicians, patients, and policymakers who are concerned that prescription drugs not only can have health side effects, but financial side effects, too.</p>
]]></description>
                                                            <content:encoded><![CDATA[<p>In a new podcast series from the Institute for Clinical and Economic Review (ICER), neurologist Dr. Jason Crowell sits down with ICER’s President Dr. Steve Pearson to pry open the black box of US drug pricing and to wrestle with each of the financial and ethical tensions that undergird our current medical infrastructure. A must-listen for physicians, patients, and policymakers who are concerned that prescription drugs not only can have health side effects, but financial side effects, too.</p>
]]></content:encoded>
                                    
        <enclosure url="https://mcdn.podbean.com/mf/web/p96bi7/ICER_Podcast_episode_0_final71sg7.mp3" length="5990490" type="audio/mpeg"/>
        <itunes:summary>In a new podcast series from the Institute for Clinical and Economic Review (ICER), neurologist Dr. Jason Crowell sits down with ICER’s President Dr. Steve Pearson to pry open the black box of US drug pricing and to wrestle with each of the financial and ethical tensions that undergird our current medical infrastructure. A must-listen for physicians, patients, and policymakers who are concerned that prescription drugs not only can have health side effects, but financial side effects, too.</itunes:summary>
        <itunes:author>Jason L. Crowell, MD Jerome H. Grossman MD Graduate Fellow, Harvard Kennedy School Neurologist, Beth Israel Deaconess Medical Center; Steve Pearson,  Founder and President, ICER, Lecturer, Department of Population Medicine, Harvard Medical School</itunes:author>
        <itunes:explicit>false</itunes:explicit>
        <itunes:block>No</itunes:block>
        <itunes:duration>249</itunes:duration>
        <itunes:season>1</itunes:season>
                <itunes:episodeType>trailer</itunes:episodeType>
            </item>
</channel>
</rss>
